{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Stable disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"After the completion of TSEBT, patients will be followed every 4 weeks until 24 weeks ,and then every 8 weeks for a total of 12 months or until there is disease progression, relapse, or the initiation of a new anti-cancer therapy.\n\nThe primary endpoint for the trial was the clinical response rate as defined by the modified severity weighted assessment tool (mSWAT) Partial response was defined as 50% improvement in the mSWAT. Complete response was complete disappearance of disease.","groups":[{"description":"Total skin electron beam therapy will be administered in the Department of Radiation Oncology according to the Stanford six-field technique. Patients will receive a planned total skin dose of 12 Gy fractionated at 2 Gy/cycle (each cycle requiring 2 days of treatment) 4 days each week, for 3 weeks. Discrete tumors may receive additional \"boost\" treatment not to exceed 12 Gy. .","id":"OG000","title":"12 Gy TSEBT"}],"paramType":"NUMBER","populationDescription":"All patients who completed treatment.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Clinical Response Rate","type":"PRIMARY","unitOfMeasure":"participants"}